Table 1.
Comparison of clinicopathological factors in non-survivors and 5-year survivors
| Factor | Non-survivors (n = 24) | 5-year survivors (n = 5) | P-value |
|---|---|---|---|
| Gender, male, n (%) | 21 (87.5%) | 4 (80.0%) | 0.3896 |
| Age, years, median (range) | 56 (29–76) | 51 (49–63) | 0.3896 |
| Total bilirubin, mg/dl, median (range) | 0.9 (0.4–4.0) | 1.1 (0.5–1.4) | 0.3133 |
| Albumin, g/dl, median (range) | 3.7 (3.1–4.9) | 3.8 (3.1–4.3) | 0.5346 |
| AST, U/l, median (range) | 65 (19–1160) | 36 (22–78) | 0.0365a |
| ALT, U/l, median (range) | 48 (10–338) | 37 (25–300) | 0.5913 |
| Positive HBVs-Ag, n(%) | 13 (54.2%) | 3 (60.0%) | 1.0000 |
| Positive HCV-Ab, n (%) | 9 (37.5%) | 3 (60.0%) | 0.6221 |
| AFP, ng/ml, median (range) | 4 001 (7–422 680) | 2 325 (152.1–98 030) | 0.1914 |
| DCP, mAU/ml, median (range) | 4 240 (24–75 000) | 1 210 (18–2028) | 0.0052a |
| DCP <2200 mAU/ml, n (%) | 10 (41.7%) | 5 (100%) | 0.0421a |
| ICGR15, %, median (range) | 12.0 (5.5–33.6) | 8.7 (1.4–24.5) | 0.1456 |
| Main tumour size, cm, median (range) | 8.5 (2.0–16.0) | 3.9 (2.2–13.0) | 0.1463 |
| Tumour differentiation, moderate, n (%) | 4 (16.7%) | 2 (40.0%) | 0.2709 |
| Intrahepatic metastasis, n (%) | 23 (95.8%) | 3 (60.0%) | 0.0684 |
| Surgical curability, n (%) | 14 (58.3%) | 5 (100%) | 0.1336 |
| Blood loss, ml, median (range) | 1 900 (493–23 000) | 1 800 (1800–12 500) | 0.5198 |
| Transfusion rate, % | 41.7% | 40.0% | 1.0000 |
a
P < 0.05.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBVs-Ag, hepatitis B virus surface antigen; HCV-Ab, hepatitis C virus antibody; AFP, alphafetoprotein; DCP, des-γ-carboxy prothrombin; ICGR15, indocyanine green retention test at 15 min.